89567-04-4

Basic information

• Product Name: 2-(CHLOROMETHYL)-5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4-AMINE
• Synonyms: 2-(CHLOROMETHYL)-5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4-AMINE;CHEMBRDG-BB 5107403;2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4-amine(SALTDATA: 2HCl);2-(ChloroMethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyriMidin-4-aMine;2-(Chloromethyl)-5,6,7,8-tetrahydro-benzothieno[2,3-d]pyrimidin-4-amine
• CAS NO: 89567-04-4
• Molecular Formula: C₁₁H₁₂ClN₃S
• Molecular Weight: 253.75
• Mol File: 89567-04-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.439g/cm³
• Refractive Index: 1.717
• CAS DataBase Reference: 2-(CHLOROMETHYL)-5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(CHLOROMETHYL)-5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4-AMINE(89567-04-4)
• EPA Substance Registry System: 2-(CHLOROMETHYL)-5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4-AMINE(89567-04-4)

Safety Data

• Hazardous Substances Data: 89567-04-4(Hazardous Substances Data)

Usage

General Description

2-(Chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4-amine is a chemical compound with the molecular formula C11H13ClN2S. It is a heterocyclic amine with a chloromethyl group attached to the benzothieno ring. 2-(CHLOROMETHYL)-5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4-AMINE is not commonly found in nature and is primarily synthesized for research purposes. It may have potential applications in pharmaceuticals or as a building block for other chemical compounds due to its unique structure. However, further research is needed to explore its potential uses and properties.

InChI:InChI=1/C11H12ClN3S/c12-5-8-14-10(13)9-6-3-1-2-4-7(6)16-11(9)15-8/h1-5H2,(H2,13,14,15)

Upstream product

• 108-94-1 cyclohexanone 
• 4651-91-6 3-cyano-2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene 
• 107-14-2 chloroacetonitrile 

Downstream Products

• 1443221-52-0 N-[5-(4-amino-5,6,7,8-tetrahydrobenzo[4,5]-thieno[2,3-d]pyrimidin-2-yl)-4-phenylthiazol-2-yl]benzamide 
• 1443221-51-9 N-[5-(4-amino-5,6,7,8-tetrahydrobenzo[4,5]-thieno[2,3-d]pyrimidin-2-yl)-4-phenylthiazol-2-yl]-4-methylbenzamide 
• 1443221-50-8 N-[5-(4-amino-5,6,7,8-tetrahydro-benzo[4,5]-thieno[2,3-d]pyrimidin-2-yl)-4-phenylthiazol-2-yl]-4-methoxybenzamide 
• 333786-73-5 4-amino-2-(4-methoxyphenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 
• 77373-45-6 4-amino-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 
• 1443221-57-5 furan-2-carboxylic acid [5-(4-amino-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-yl)-4-phenylthiazol-2-yl]amide 

Relevant articles and documents

For FGFR1 tetrahydroben-and thieno [2, 3 - d] amino pyrimidine derivative and its preparation method and application

The invention relates to tetrahydrobenzothieno[2,3-d]aminopyrimidine derivatives acting on FGFR1, and a preparation method and application thereof. The structure of the tetrahydrobenzothieno[2,3-d]aminopyrimidine derivatives is disclosed as Formula (I). The anti-apoptosis experiment research on the three cells H460 (human lung cancer cell), A549 (human lung adenocarcinoma cell) and U251 (glioma cell) indicates that all the detected compounds have certain inhibition activity, and the inhibition activity increases as the concentration increases. Meanwhile, the FGFR1 kinase inhibition activity experiment indicates that the compounds have certain antitumor activity.

New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides

A series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamide and furamide analogues were investigated in radioligand binding studies at adenosine receptor subtypes with an aim to obtain potent and selective adenosine receptor ligands. Benzamide and furamide linked to thiazole was found to be crucial for high adenosine receptor affinity. The most potent compound indentified in this study was 5d with low nanomolar affinity for all four adenosine receptor subtypes. Compounds 5a and 5g showed moderate selectivity for A2A adenosine receptors. Molecular docking versus all four human adenosine receptors combined with membrane molecular dynamics studies were performed to rationalise the peculiar selectivity profile of 5d antagonist.